Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Homozygous familial hypercholesterolemia: Summarized case reports.

Widhalm K, Benke IM, Fritz M, Geiger H, Helk O, Fritsch M, Hoermann G, Kostner G.

Atherosclerosis. 2017 Feb;257:86-89. doi: 10.1016/j.atherosclerosis.2017.01.002. Epub 2017 Jan 18.

PMID:
28126585
2.

Long-term outcome in 53 patients with homozygous familial hypercholesterolaemia in a single centre in France.

Bruckert E, Kalmykova O, Bittar R, Carreau V, Béliard S, Saheb S, Rosenbaum D, Bonnefont-Rousselot D, Thomas D, Emery C, Khoshnood B, Carrié A.

Atherosclerosis. 2017 Feb;257:130-137. doi: 10.1016/j.atherosclerosis.2017.01.015. Epub 2017 Jan 16.

PMID:
28131047
3.

Homozygous familial hypercholesterolemia in childhood: Genotype-phenotype description, established therapies and perspectives.

Sanna C, Stéphenne X, Revencu N, Smets F, Sassolas A, Di Filippo M, Descamps OS, Sokal EM.

Atherosclerosis. 2016 Apr;247:97-104. doi: 10.1016/j.atherosclerosis.2016.02.009. Epub 2016 Feb 5.

PMID:
26894473
4.

A nation-wide survey of patients with homozygous familial hypercholesterolemia phenotype undergoing LDL-apheresis in Turkey (A-HIT 1 registry).

Kayikcioglu M, Tokgozoglu L, Yilmaz M, Kaynar L, Aktan M, Durmuş RB, Gokce C, Temizhan A, Ozcebe OI, Akyol TK, Okutan H, Sag S, Gul OO, Salcioglu Z, Yenercag M, Altunkeser BB, Kuku I, Yasar HY, Kurtoglu E, Kose MD, Demircioglu S, Pekkolay Z, Ilhan O.

Atherosclerosis. 2018 Mar;270:42-48. doi: 10.1016/j.atherosclerosis.2018.01.034. Epub 2018 Jan 31.

PMID:
29407887
5.

Managing homozygous familial hypercholesterolaemia from cradle to grave.

Thompson GR.

Atheroscler Suppl. 2015 May;18:16-20. doi: 10.1016/j.atherosclerosissup.2015.02.002. Review.

PMID:
25936299
6.

HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom.

France M, Rees A, Datta D, Thompson G, Capps N, Ferns G, Ramaswami U, Seed M, Neely D, Cramb R, Shoulders C, Barbir M, Pottle A, Eatough R, Martin S, Bayly G, Simpson B, Halcox J, Edwards R, Main L, Payne J, Soran H; for HEART UK Medical Scientific and Research Committee.

Atherosclerosis. 2016 Dec;255:128-139. doi: 10.1016/j.atherosclerosis.2016.10.017. Epub 2016 Nov 5. Review.

7.

Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment.

Raal FJ, Santos RD.

Atherosclerosis. 2012 Aug;223(2):262-8. doi: 10.1016/j.atherosclerosis.2012.02.019. Epub 2012 Feb 16. Review.

PMID:
22398274
8.

Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society.

Cuchel M, Bruckert E, Ginsberg HN, Raal FJ, Santos RD, Hegele RA, Kuivenhoven JA, Nordestgaard BG, Descamps OS, Steinhagen-Thiessen E, Tybjærg-Hansen A, Watts GF, Averna M, Boileau C, Borén J, Catapano AL, Defesche JC, Hovingh GK, Humphries SE, Kovanen PT, Masana L, Pajukanta P, Parhofer KG, Ray KK, Stalenhoef AF, Stroes E, Taskinen MR, Wiegman A, Wiklund O, Chapman MJ; European Atherosclerosis Society Consensus Panel on Familial Hypercholesterolaemia.

Eur Heart J. 2014 Aug 21;35(32):2146-57. doi: 10.1093/eurheartj/ehu274. Epub 2014 Jul 22.

9.

High serum triglyceride concentrations in patients with homozygous familial hypercholesterolemia attenuate the efficacy of lipoprotein apheresis by dextran sulfate adsorption.

Drouin-Chartier JP, Tremblay AJ, Bergeron J, Lamarche B, Couture P.

Atherosclerosis. 2018 Mar;270:26-32. doi: 10.1016/j.atherosclerosis.2018.01.005. Epub 2018 Jan 12.

PMID:
29407885
10.

Multimodal lipid-lowering treatment in pediatric patients with homozygous familial hypercholesterolemia-target attainment requires further increase of intensity.

Klaus G, Taylan C, Büscher R, Schmitt CP, Pape L, Oh J, Driemeyer J, Galiano M, König J, Schürfeld C, Spitthöver R, Schaefer JR, Weber LT, Heibges A, Klingel R.

Pediatr Nephrol. 2018 Jul;33(7):1199-1208. doi: 10.1007/s00467-018-3906-6. Epub 2018 Mar 3.

PMID:
29502162
11.

First case report of familial hypercholesterolemia in an Omani family due to novel mutation in the low-density lipoprotein receptor gene.

Al-Hinai AT, Al-Abri A, Al-Dhuhli H, Al-Waili K, Al-Sabti H, Al-Yaarubi S, Al-Hashmi K, Banerjee Y, Al-Zakwani I, Al-Rasadi K.

Angiology. 2013 May;64(4):287-92. doi: 10.1177/0003319712465171. Epub 2012 Nov 15.

PMID:
23162007
12.

Treatment of homozygous familial hypercholesterolaemia in paediatric patients: A monocentric experience.

Buonuomo PS, Macchiaiolo M, Leone G, Valente P, Mastrogiorgio G, Gnazzo M, Rana I, Gonfiantini MV, Gagliardi MG, Romano F, Bartuli A.

Eur J Prev Cardiol. 2018 Jul;25(10):1098-1105. doi: 10.1177/2047487318776836. Epub 2018 May 22.

PMID:
29785886
13.

Apheresis in homozygous familial hypercholesterolemia: the results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia.

Græsdal A, Bogsrud MP, Holven KB, Nenseter MS, Narverud I, Langslet G, Brekke M, Retterstøl K, Arnesen KE, Ose L.

J Clin Lipidol. 2012 Jul-Aug;6(4):331-9. doi: 10.1016/j.jacl.2012.03.004. Epub 2012 Mar 23.

PMID:
22836070
14.

The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial.

Stefanutti C, Blom DJ, Averna MR, Meagher EA, Theron Hd, Marais AD, Hegele RA, Sirtori CR, Shah PK, Gaudet D, Vigna GB, Sachais BS, Di Giacomo S, du Plessis AM, Bloedon LT, Balser J, Rader DJ, Cuchel M; Phase 3 HoFH Lomitapide Study Investigators.

Atherosclerosis. 2015 Jun;240(2):408-14. doi: 10.1016/j.atherosclerosis.2015.03.014. Epub 2015 Mar 14.

15.

Phenotype diversity among patients with homozygous familial hypercholesterolemia: A cohort study.

Raal FJ, Sjouke B, Hovingh GK, Isaac BF.

Atherosclerosis. 2016 May;248:238-44. doi: 10.1016/j.atherosclerosis.2016.03.009. Epub 2016 Mar 11.

16.

Inhibition of hepatic microsomal triglyceride transfer protein - a novel therapeutic option for treatment of homozygous familial hypercholesterolemia.

Vuorio A, Tikkanen MJ, Kovanen PT.

Vasc Health Risk Manag. 2014 May 6;10:263-70. doi: 10.2147/VHRM.S36641. eCollection 2014. Review.

17.

The Low-Density Lipoprotein Receptor Genotype Is a Significant Determinant of the Rebound in Low-Density Lipoprotein Cholesterol Concentration After Lipoprotein Apheresis Among Patients With Homozygous Familial Hypercholesterolemia.

Drouin-Chartier JP, Tremblay AJ, Bergeron J, Lamarche B, Couture P.

Circulation. 2017 Aug 29;136(9):880-882. doi: 10.1161/CIRCULATIONAHA.117.029435. No abstract available.

PMID:
28847800
18.

Pregnancy in homozygous familial hypercholesterolemia--Importance of LDL-apheresis.

Blaha M, Lanska M, Blaha V, Boudys L, Zak P.

Atheroscler Suppl. 2015 May;18:134-9. doi: 10.1016/j.atherosclerosissup.2015.02.024.

PMID:
25936317
19.

Spectrum of mutations in homozygous familial hypercholesterolemia in India, with four novel mutations.

Setia N, Saxena R, Arora A, Verma IC.

Atherosclerosis. 2016 Dec;255:31-36. doi: 10.1016/j.atherosclerosis.2016.10.028. Epub 2016 Oct 14.

PMID:
27816806
20.

The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis.

Leipold R, Raal F, Ishak J, Hovingh K, Phillips H.

Eur J Prev Cardiol. 2017 Nov;24(17):1843-1850. doi: 10.1177/2047487317730473. Epub 2017 Sep 19.

PMID:
28925748

Supplemental Content

Support Center